Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "terapia w chorobie nowotworowej" wg kryterium: Temat


Wyświetlanie 1-1 z 1
Tytuł:
Metaloproteinazy – znaczenie w procesie nowotworzenia, diagnostyce i terapii
Metalloproteinases – importance in cancer development, diagnostics and therapy
Autorzy:
Pietrzak, Jacek
Mirowski, Marek
Powiązania:
https://bibliotekanauki.pl/articles/771742.pdf
Data publikacji:
2015
Wydawca:
Łódzkie Towarzystwo Naukowe
Tematy:
cancer
therapy.
cancer diagnostics
carcinogenesis
diagnostyka
nowotworowa
kancerogeneza
metalloproteinases
metaloproteinazy
terapia w chorobie nowotworowej
Opis:
Metalloproteinases (MMP) are proteolytic enzymes whose activity is determined by the presence of zinc ion in the active site and are a widely distributed family of protease to ensure the preservation of homeostasis in animals. In human body they also play many important functions participating in the process of embryogenesis as well as in the formation of blood cells or bone formation. The main role, as it seemed at the beginning research on this group of enzymes, was to digest the extracellular matrix. However, over the years, it turned out that metalloproteinases are important part in the regulation of cell biology, in particular a tumor cell. Studies have confirmed the participation of metalloproteinases in all stages of the process of carcinogenesis. At the moment, there are numerous reports of available of various MMPs in different tumors. However, two of these MMP–2 and MMP–9 belonging to the gelatinases seem to be the most common. It has been confirmed also that higher levels usually indicate a worse prognosis for the patient. Therefore, they may prove to be a valuable prognostic indication for clinicians. Attention was paid to the potential use of matrix metalloproteinases in targeted therapy. The pharmaceutical industry has long been trying to launch metalloproteinase inhibitors as possible therapeutics in cancer, seeing in them a potential that, however, is limited to the early stages of development. After initial setbacks related primarily to the low selectivity is used at once more modern methods as monoclonal antibodies or liposomal drug delivery system. Thus, giving the possibility of treatment that does not cause so enormous side effects as conventional therapy.
Źródło:
Folia Medica Lodziensia; 2015, 42, 1; 33-48
0071-6731
Pojawia się w:
Folia Medica Lodziensia
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-1 z 1

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies